Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Tax Provisions for 3 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions changed N/A to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.6 million for FY2025, N/A changed from the prior year.
  • Tax Provisions for Q4 2025 was $1.0 million at Akebia Therapeutics, up from $615000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $1.0 million in Q4 2025, with the low at $615000.0 in Q3 2025.